knowcompoundsN-acetyl-L-cysteine
Specimen compound organic compoundPlate I
N- acetyl- L- cysteine

- Formula
- C5H9NO3S
- Molar mass
- 163.198 g/mol
- ChEBI
- CHEBI:28939
- PubChem CID
- 12035
- InChIKey
- PWKSKIMOESPYIA-BYPYZUCNSA-N
↑ raised 1 finding in 1 endpoint · ↓ lowered 3 in 3 · – no difference found 4 in 3
01 · the evidence, ordered
What the evidence says
- Strong
- 1
- Moderate
- 6
- Limited
- 1
- Very limited
- 0
- Insufficient
- 0
N-acetyl-L-cysteine
Most findings
- All-cause mortality×3
- Acute kidney injury incidence (any grade)×1
- Clinical pregnancy rate×1
- Hospital length of stay×1
- Serum creatine kinase activity×1
- Tumour necrosis factor alpha concentration×1
2 reference statements, not drawn · 36 compounds on the outer ring, not drawn
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
- All-cause mortalitycontested
- Acute kidney injury incidence (any grade)
- Clinical pregnancy rate
- Hospital length of stay
- Serum creatine kinase activity
- Tumour necrosis factor alpha concentration
02 · contested · 1 endpoint
Where the findings disagree
013 findings
All-cause mortality
03 · findings
What N-acetyl-L-cysteine moved, and by how much
- RR risk ratio · MD mean difference · OR odds ratio. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
8 shown
- All-cause mortalitycontestedMoved: no difference foundEffect, as reportedRR0.71[0.4 to 1.25]Evidence: Strongreplicated ×1Paper: PMID 310710812019
- Who
- Adults undergoing on-pump or off-pump cardiac surgery, 17 randomised trials pooled, NAC added to standard of care versus standard of care with or without placebo; routes pooled (intravenous, cardioplegia, oral) · n = 1,737
- Dose studied
- not reported
Results from 17 RCTs including 1,737 patients yielded a non-statistically significant difference between NAC and SoC on the reduction of mortality (RR 0.71, 95% CI 0.40 to 1.25; events (NAC:20/870, SoC:33/867); I2 = 0%; p = 0.23).”
Quoted verbatim from N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials.meta-analysisPermalink - Tumour necrosis factor alpha concentrationMoved: no difference foundEvidence: ModeratePaper: PMID 396322672024
- Who
- Participants in pooled studies of NAC supplementation, concentrations after physical exertion
- Dose studied
- not reported
However, we saw no significant effect of NAC on TNF-α, CK or GSSG concentrations.”
Quoted verbatim from The impact of N-acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta-analysis.meta-analysisPermalink - Hospital length of stayMoved: lowersEffect, as reportedMD−3.84[−7.44 to −0.24]Evidence: ModeratePaper: PMID 427807692026
- Who
- Critically ill ICU patients with underlying respiratory disease; pooled across 2 randomized trials, NAC in addition to standard care versus placebo or regimens without NAC; reported in days
- Dose studied
- not reported
However, pooled data from 2 studies assessing hospital LOS indicated a significantly shorter LOS in the NAC group than in the control group (MD = −3.84 days; 95% CI: −7.44 to −0.24; Table 3).”
Quoted verbatim from Clinical effects of N-acetylcysteine in ICU patients with respiratory disease: a systematic review and meta-analysis.meta-analysisPermalink - Acute kidney injury incidence (any grade)Moved: lowersEffect, as reportedRR0.51[0.31 to 0.82]Evidence: ModeratePaper: PMID 330672892020
- Who
- Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, seven randomised trials pooled
- Dose studied
- not reported
Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01) and all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01).”
Quoted verbatim from Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.meta-analysisPermalink - Serum creatine kinase activityMoved: no difference foundEvidence: ModeratePaper: PMID 396322672024
- Who
- Participants in pooled studies of NAC supplementation, concentrations after physical exertion
- Dose studied
- not reported
However, we saw no significant effect of NAC on TNF-α, CK or GSSG concentrations.”
Quoted verbatim from The impact of N-acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta-analysis.meta-analysisPermalink - Clinical pregnancy rateMoved: raisesEvidence: ModeratePaper: PMID 394152422024
- Who
- Women aged 21 to 38 with polycystic ovary syndrome and anovulation or oligo-ovulation undergoing letrozole plus urinary FSH ovulation induction (up to three cycles) in both arms; pragmatic open-label trial with blinded outcome assessors and a no-NAC control group (human arm only)
- Dose studied
- 1.8 g/day oral (0.6 g three times daily) from day 2 to 4 of the cycle for five consecutive days, each induction cycle
In the comparison of clinical pregnancy rates, both per OI cycle and cumulative per patient, the rates in the NAC group were significantly greater than those in the control group (30.99% vs. 23.30%, p = 0.040; and 77.88% vs. 58.04%, p = 0.001, respectively).”
Quoted verbatim from N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome.RCTPermalink - All-cause mortalitycontestedMoved: no difference foundEffect, as reportedOR0.85[0.43 to 1.68]Evidence: Moderatereplicated ×1Paper: PMID 347326002022
- Who
- Adults undergoing cardiac surgery, eight randomised trials pooled, NAC versus placebo; in-hospital mortality horizon
- Dose studied
- not reported
Meta-analytic estimates for in-hospital mortality showed that there was no statistically significant difference between patients treated with NAC and without, as shown in Supplemental Fig. 6 (OR: 0.85, 95% CI: 0.43–1.68).”
Quoted verbatim from N-Acetylcysteine's Renoprotective Effect in Cardiac Surgery: A Systematic Review and Meta-Analysis.meta-analysisPermalink - All-cause mortalitycontestedMoved: lowersEffect, as reportedRR0.37[0.17 to 0.79]Evidence: LimitedPaper: PMID 330672892020
- Who
- Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, seven randomised trials pooled; in-hospital mortality horizon
- Dose studied
- not reported
Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01) and all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01).”
Quoted verbatim from Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.meta-analysisPermalink
No row matches these filters.
No dose is advised.
- RR risk ratio · MD mean difference · OR odds ratio. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
04 · identity
Structure
- Charge
- 0
- SMILES
- CC(=O)N[C@@H](CS)C(=O)O
05 · figures · 1 plate
Plates

fig. 5N-acetyl-L-cysteine · MS2 [M-H]- LC-ESI-ITFT negative · MassBank MSBNK-mFam-MC20_000175 (Stacey N Reinke, CC BY)
06 · reach
What it touches on the way
1 entity · assembled from reference reactions
- NAGSProtein11 paths · 11 endpointsinferred
What the reference databases state
2Reference statements
What the reference databases state
Evidence keyStatements
2 statements
Sources: Human-GEM, Rhea
- N-acetyl-L-cysteine is a substrate of NAGSProteinHuman-GEM MAR05419Inferred only
- N-acetyl-L-cysteine is transported by SLC7A11ProteinRhea RHEA:74567Inferred only
13Reactions
08 · on the label · 1,558 products
Labelled products
Source: NIH DSLD · Ingredient: N-acetyl-L-cysteine · 1,558 products · Declared amount per serving (the first 1,000 shown): 0.25–1,800 mg
794 labels of the first 1,000 shown state an amount206 do not
- 'Merica LabzGuts 'N Glory Gut Punch600 mgper 5.1 gDSLD:213374
- 1MDImmunityMD+600 mgper 1 capsuleDSLD:246766
- 1st PhormLiver Detox1,200 mgper 5 capsulesDSLD:242910
- 1st PhormRemedyamount not statedper 5 capsulesDSLD:242989
- 20S20 NutritionSuper Natural PCTamount not statedper 2 capsulesDSLD:286854
- 4LifeFibro AMJ Day Time Formulaamount not statedper 3 capsulesDSLD:249650
- 4LifeReCallamount not statedper 3 capsulesDSLD:248412
- 4LifeSleepRite AMJamount not statedper 2 capsulesDSLD:249818
- 8WeeksOutNRF2Guard 1125 mgamount not statedper 2 capsulesDSLD:228521
- 8WeeksOutTestogenXamount not statedper 2 capsulesDSLD:228469
- AB American BiologicsOxy-5000 Forte10 mgper 2 tabletsDSLD:20260
- AB American BiologicsOxy-5000 Forte10 mgper 2 tabletsDSLD:20268
Show the remaining 1,546Show the first 12
Label record: NIH Office of Dietary Supplements · CC0
09 · the record
Sources
894
papers screened for N-acetyl-L-cysteine
- admitted
- 8
- read and discarded
- 234
- not read yet
- 652
Sources cited
6 papers · 8 findings
2 admitted at screening, no finding yet